ArticleMolecular biology reports2026
Digital multiplex ligation-dependent probe amplification identifies exon-level copy number variants in patients with suspected hereditary cancer and negative next-generation sequencing results.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundNext-generation sequencing (NGS) has improved hereditary cancer diagnostics, but exon-level copy number variants (CNVs) may remain undetected because of uneven read depth or limitations of CNV-calling algorithms. Digital multiplex ligation-dependent probe amplification (digital MLPA) offers exon-level CNV assessment across multiple genes in a single experiment. This study evaluated whether digital MLPA can resolve cases with strong hereditary cancer features but negative multigene NGS results. METHODS AND
resultsForty-eight patients with clinical suspicion of hereditary cancer and previously negative NGS panel testing were analyzed using the Hereditary Cancer Panel 1 (D001–D1, MRC Holland). Internal positive and negative controls were used to confirm assay performance. Digital MLPA identified clinically relevant CNVs in four unrelated families, corresponding to an additional diagnostic yield of 8.5% (4/47 informative families). The detected CNVs involved MLH1, and CDKN2A, each showing clear molecular or clinical correlation through tumor immunohistochemistry, segregation patterns, or personal/family history. All CNVs would have remained undetected if testing relied solely on sequencing-based pipelines. Additionally, a single-exon PMS2 deletion initially detected by both digital and conventional MLPA was subsequently re-evaluated and reclassified as a technical artifact following identification of a ligation-site SNV by NGS read inspection.
conclusionsDigital MLPA revealed clinically relevant CNVs in a subset of NGS-negative patients, demonstrating that structural variants continue to represent an important diagnostic blind spot. While the method proved practical for routine workflow integration, our findings highlight a critical pitfall regarding single-exon deletions. Since concordance between MLPA platforms does not rule out artifacts caused by ligation-site variants, visual inspection of NGS data is an essential validation step. Incorporating digital MLPA as a second-tier assay, with rigorous confirmation of single-probe findings, offers a robust strategy to improve genetic counseling and risk management.
Indexed as
Identifiers
41697536What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.